SavedAdd your journal

Journals / Turkish journal of physical medicine and rehabilitation / 2019 / Cilt: 65 - Sayı: 2

Recurrent uveitis under golimumab treatment in a patient diagnosed with axial spondyloarthritis: Is it a paradoxical effect?

Alper MENGİ
Şenay ÖZDOLAP
Hande ORAY
Selda SARIKAYA
Pages
191–193
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein, we report the first case of axial spondyloarthropathy in whom recurrent attacks ofpanuveitis paradoxically developed under golimumab treatment in the light of literature data.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Anti-tumor necrosis factor drugs are highly effective in the treatment of spondyloarthropathies.
📊
Key Findings & Data:In recent years, there have been reports ofparadoxical effects with the use of these drugs.
💡
Conclusion & Impact:Herein, we report the first case of axial spondyloarthropathy in whom recurrent attacks ofpanuveitis paradoxically developed under golimumab treatment in the light of literature data.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Anti-tumor necrosis factor drugs are highly effective in the treatment of spondyloarthropathies. In recent years, there have been reports ofparadoxical effects with the use of these drugs. Herein, we report the first case of axial spondyloarthropathy in whom recurrent attacks ofpanuveitis paradoxically developed under golimumab treatment in the light of literature data.

🔖

Cite This Article

MENGİ, A., ÖZDOLAP, Ş., ORAY, H., SARIKAYA, S. (2019). Recurrent uveitis under golimumab treatment in a patient diagnosed with axial spondyloarthritis: Is it a paradoxical effect?. Turkish journal of physical medicine and rehabilitation, Cilt: 65 - Sayı: 2, 191–193. https://ajindex.com/articles/375259

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008;67:955-9
  2. Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2016;2:e000239
  3. Kay J, Rahman MU. Golimumab: A novel human anti-TNFalpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid 2010;4:159-70
  4. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of Spondylo Arthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83
  5. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4
  6. Faez S, Lobo AM, Sobrin L, Papaliodis GN. Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Exp Ophthalmol 2014;42:392-5
  7. Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 2009;48:761-4
  8. Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume- Czitrom S, Prati C, et al. New onset of uveitis during antitumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10
  9. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52.